ÌÇÐÄvlog´«Ã½

Tacrolimus Market Analysis

The tacrolimus market is expected to register a CAGR of 5.2% over the forecast period, 2022-2027.

The COVID-19 pandemic has had a significant impact on the growth of the tacrolimus market. Due to stricter lockdowns and stringent social distancing norms, most of the patient population was restricted from undergoing organ transplant procedures globally. This greatly reduced the overall adoption rate of tacrolimus medications worldwide since most of the surgeries and transplantations were either postponed or delayed. For instance, as per the article titled "Kidney Transplantation in COVID Pandemic-A Review of Guidelines" published in the National Library of Medicine, in June 2021, the COVID-19 infection has had a severe impact on transplantation protocols and programs. In 2020, the number of transplants had significantly decreased. Likewise, another article titled "Organ procurement and transplantation during the COVID-19 pandemic" published in the same journal stated that the surge in COVID-19 infections and a startling decline in overall solid-organ transplantation procedures were found to have a clear temporal correlation, according to the researchers. There have been 90.6 percent fewer transplants using deceased donors in France and 51.1 percent fewer in the United States since the COVID-19 epidemic. This decrease was mostly caused by kidney transplantation in both France and the United States, but there was also a sizable impact on heart, lung, and liver transplants as well. In addition, as per the data published by the Global Observatory on Donation and Transplantation, in 2020, there were approximately 17.6% fewer transplants in 2020 as compared with the previous year, that is 2019. Thus, the COVID-19 outbreak affected the market's growth adversely in its preliminary phase; however, owing to treatment guidelines and precautionary measures released by several organizations and regulatory bodies for combatting COVID-19 in these procedures, the market is anticipated to gain traction over the coming years.

In addition, the increasing number of transplants worldwide and the surge in research and development activities for immunosuppression are likely to have a positive impact on the growth of the studied market.

Tacrolimus is administered in the management of allograft recipients receiving immunosuppressive drug therapy; thus, it plays a vital role in organ transplantation procedures. According to the data published by the Global Observatory on Donation and Transplantation, in 2020 there were a total of 1,29,681 organ transplants performed worldwide. Similarly, according to Australian and New Zealand Organ Donor Registry (ANZOD) data, in 2021, 657 kidney transplants, 253 liver transplants, 171 lung transplants, and 152 other organ transplant procedures were performed in Australia alone. Such an increase in the number of transplant procedures is expected to boost the acceptance of tacrolimus medications, in turn, driving the market growth over the forecast period.

Moreover, a surge in research and development activities, product launches, and approvals is anticipated to augment the growth of the market over the coming years. For instance, in July 2021, the enrolment for the Phase 1 clinical study for Tacrolimus Inhalation Powder was completed by TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on creating and marketing cutting-edge medical products.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the side effects of the tacrolimus drugs are likely to impede the market growth.

Tacrolimus Market Trends

This section covers the major market trends shaping the Tacrolimus Market according to our research experts:

Immunosuppression Segment is Expected to Witness Growth over the Forecast Period

Tacrolimus Industry Segmentation

As per the scope of the report, tacrolimus is a member of the class of drugs referred to as immunosuppressants. In order to reduce allergic reactions and prevent organ transplant rejection, the drug is used to effectively suppress the immune system. The tacrolimus market is segmented by Product Type (Tablets and Capsules, Injections, and Others), Application (Immunosuppression, Dermatitis, and Others), End Users (Hospitals, Clinics, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments. The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally.